Form 4: Celldex Therapeutics Director Acquires Stock Options

James J. Marino, a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024, under the company's 2021 Omnibus Equity Incentive Plan.

Summary

• James J. Marino, a director of Celldex Therapeutics, filed a Form 4 on June 17, 2024, reporting a transaction.
• On June 13, 2024, Marino acquired 16,500 non-qualified stock options with an exercise price of $36.43.
• These options, granted under the 2021 Omnibus Equity Incentive Plan, vest on June 13, 2025, and expire on June 13, 2034.
• Following the transaction, Marino directly owns 16,500 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard transaction (stock option grant) for a company director. It doesn't inherently indicate positive or negative performance, but rather aligns with typical executive compensation practices.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment, as it may signal confidence in the company's future.

Key Dates